{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-004837","form_type":"8-K","ticker":null,"cik":"0001442999","company_name":"ALTEROLA BIOTECH INC.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.313121+00:00","generated_at":"2026-05-18T12:33:43.688581+00:00","sec_items":["1.01","2.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alterola sells Phytanix to Protagenic, plans to deregister; directors resign","bullets":["Alterola and EMC2 sold 100% of Phytanix to Protagenic for Protagenic common and preferred stock; combined ownership: 35% existing Protagenic, 65% Alterola/EMC2.","Alterola shareholders will be offered the option to swap ABTI shares for Protagenic shares; shareholder vote required by September 1, 2025.","Alterola intends to terminate SEC registration and become a privately held company to reduce costs.","Executive Chairman Tim Rogers, CEO David Hitchcock, CFO Nathan Thompson, and three independent directors resigned; Dominic Schiller and Colin Stott remain."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-004837","json":"https://secwatch.observer/filing/0001477932-25-004837.json","markdown":"https://secwatch.observer/filing/0001477932-25-004837.md","text":"https://secwatch.observer/filing/0001477932-25-004837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/0001477932-25-004837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/abti_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:33:43.688581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfa700a3a9067bb5be9ade1f7746148f954c5250","claim":"ALTEROLA BIOTECH INC. completed a disposition involving Protagenic Therapeutics, Inc. for shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants (closed 2025-05-16).","evidence_excerpt":"On May 16, 2025, Alterola, EMC2, and the Preferred Stockholders completed its business combination with Protagenic.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/0001477932-25-004837-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Protagenic Therapeutics, Inc."},{"label":"Consideration","value":"shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants"},{"label":"Closing","value":"2025-05-16"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}